

Lorzone (chlorzoxazone) - Drug Summary

Vertical Pharmaceuticals Inc.

Jump to Section

[THERAPEUTIC CLASS](#)

[DEA CLASS](#)

[ADULT DOSAGE & INDICATIONS](#)

[ADMINISTRATION](#)

[HOW SUPPLIED](#)

[View All Sections...](#)

Related Drug Information

Lorzone (chlorzoxazone)

THERAPEUTIC CLASS

Muscular analgesic (centrally acting)

DEA CLASS

RX

ADULT DOSAGE & INDICATIONS

Musculoskeletal Conditions

Adjunct to rest, physical therapy, and other measures for relief of discomfort associated w/ acute, painful musculoskeletal conditions

375mg Tab:

Usual: 1 tab tid or qid

Titrate: May increase to 2 tabs (750mg) tid or qid if adequate response is not obtained

Dosage can be reduced as improvement occurs

750mg Tab:

Usual: 1/3 tab (250mg) tid or qid. Give 2/3 tab (500mg) tid or qid for painful musculoskeletal conditions

Titrate: May increase to 1 tab (750mg) tid or qid if adequate response is not obtained

Dosage can be reduced as improvement occurs

ADMINISTRATION

Oral route

HOW SUPPLIED

Tab: 375mg, 750mg

WARNINGS/PRECAUTIONS

Serious (including fatal) hepatocellular toxicity reported rarely; d/c immediately if any signs/symptoms of hepatotoxicity or abnormal liver enzymes develop. Caution w/ known allergies or w/ history of allergic reactions to drugs; d/c if a sensitivity reaction occurs.

ADVERSE REACTIONS

Drowsiness, dizziness, lightheadedness, malaise, overstimulation.

DRUG INTERACTIONS

May have additive effect w/ alcohol or other CNS depressants.

PREGNANCY AND LACTATION

Safety not known in pregnancy/nursing.

MECHANISM OF ACTION

Muscular analgesic (centrally acting); acts primarily at the level of the spinal cord and subcortical areas of the

Advertisement

TAKE A DIFFERENT APPROACH TO TREATING OBESITY

START NOW »

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2015 Novo Nordisk. All rights reserved.
0315-0025786-1 May 2015

brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology.

PHARMACOKINETICS

Absorption: T_{max} =1-2 hrs. **Metabolism:** Rapid; glucuronidation. **Elimination:** Urine (<1% unchanged).

ASSESSMENT

Assess for intolerance to chlorzoxazone, known allergies or history of allergic reactions to drugs, hepatic impairment, pregnancy/nursing status, and possible drug interactions.

MONITORING

Monitor for signs/symptoms of hepatotoxicity, sensitivity reactions, and other adverse reactions. Monitor LFTs.

PATIENT COUNSELING

Inform of the risks and benefits of therapy. Instruct to d/c immediately and contact physician if signs/symptoms of hepatotoxicity (eg, fever, rash, right upper quadrant pain, dark urine) or a sensitivity reaction (eg, urticaria, redness, itching of the skin) occur.

STORAGE

20-25°C (68-77°F).

[Back to top](#)

[About Us](#) | [Help](#) | [Contact Us](#) | [Order Books](#) | [Report Adverse Events](#) | [Privacy Policy](#) | [Terms of Service](#)

US-based MDs, DOs, NPs and PAs in full-time patient practice can register for free on PDR.net. PDR.net is to be used only as a reference aid. It is not intended to be a substitute for the exercise of professional judgment. You should confirm the information on the PDR.net site through independent sources and seek other professional guidance in all treatment and diagnosis decisions.

© 2015 PDR, LLC. All rights reserved.

